This application for a FIRST Award is a continuation and enhancement of the research program begun under the applicant's Clinical Mental Health Academic Award (KO7 MHO1O4O). The overarching goal of this research is to improve acute pharmacotherapy for severe behavioral disturbances requiring hospitalization, in patients diagnosed with Dementia of the Alzheimer's Type (DAT). The behavioral complications of DAT are among the most distressing problems confronting elderly patients and their families. A five-year double-blind, placebo-controlled trial of the most selective and highly potent serotonin reuptake inhibitor (citalopram) and standard neuroleptic pharmacotherapy (perphenazine) will be conducted in 112 DAT inpatients. It is believed that both medications will have efficacy in the acute treatment of severe behavioral disturbances. Nonetheless, it is anticipated that the use of perphenazine, a dopamine receptor blocking agent, in a population that already has significantly reduced dopaminergic function, might lead to more adverse consequences than the use of citalopram. This protocol will also examine drug metabolic covariates of treatment tolerance and platelet serotonergic correlates of response. Phenotyping for debrisoquine hydroxylase (P450 2D6) and S-mephenytoin hydroxylase (P450 2C19) will be employed to identify those at risk of adverse medication side effects. These enzymes are constitutionally deficient in as many as 20% of the population. They are also subject to variable and largely unquantified degrees of inhibition in older patients taking multiple medications. The relationship between neuroreceptor indices of serotonergic function and neurochemically specific pharmacotherapy for behavioral disturbances in DAT-afflicted patients will be examined through assessment of platelet serotonin transporters and serotonin-2 receptors. It is postulated that patients, with lower pretreatment serotonin transporter binding values, will respond preferentially to citalopram and that these patients will show a reduction in the density of their serotonin-2 receptors in response to medication. In contrast, peripheral serotonin indices will not be associated with treatment response to perphenazine. The research conducted under this proposal will lay the basis for new therapeutic approaches, such as the identification of patients who might respond preferentially to a serotonergic drug or the recognition, prior to treatment, that a patient with poor drug metabolic capacity will have diminished tolerance to standard doses of psychotropic medication. Improved treatment of behavioral complications would reduce excess disability in DAT patients, allowing them to be maintained in the community for greater periods of time.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29MH055106-05
Application #
2890743
Study Section
Mental Disorders of Aging Review Committee (MDA)
Program Officer
Olin, Jason T
Project Start
1995-09-30
Project End
2000-04-30
Budget Start
1999-05-01
Budget End
2000-04-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Psychiatry
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Kastango, Kari B; Kim, Yookyung; Dew, Mary Amanda et al. (2002) Verification of scale sub-domains in elderly patients with dementia: a confirmatory factor-analytic approach. Am J Geriatr Psychiatry 10:706-14
Pollock, Bruce G; Mulsant, Benoit H; Rosen, Jules et al. (2002) Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 159:460-5
Murphy Jr, G M; Pollock, B G; Kirshner, M A et al. (2001) CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 25:737-43
Chengappa, K N; Pollock, B G; Parepally, H et al. (2000) Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol 20:311-6
Sweet, R A; Pollock, B G; Mulsant, B H et al. (2000) Pharmacologic profile of perphenazine's metabolites. J Clin Psychopharmacol 20:181-7
Sweet, R A; Pollock, B G (1998) New atypical antipsychotics. Experience and utility in the elderly. Drugs Aging 12:115-27
Pollock, B G; Mulsant, B H; Nebes, R et al. (1998) Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am J Psychiatry 155:1110-2
Solai, L K; Mulsant, B H; Pollock, B G et al. (1997) Effect of sertraline on plasma nortriptyline levels in depressed elderly. J Clin Psychiatry 58:440-3
Mulsant, B H; Foglia, J P; Sweet, R A et al. (1997) The effects of perphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients. J Clin Psychopharmacol 17:318-21
Pollock, B G; Mulsant, B H; Sweet, R et al. (1997) An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations. Am J Geriatr Psychiatry 5:70-8